Final answer:
The results of female vaccination against HPV since the introduction of Gardasil and Cervarix vaccines have been significant, with a reduction in HPV infection rates by at least half for the targeted strains, contributing to lower rates of cervical cancer.
Step-by-step explanation:
The introduction of the HPV vaccine in 2006 has led to significant outcomes in public health, especially in the reduction of HPV infection rates among females. The two vaccines, Gardasil® and Cervarix®, were initially targeted at females, as HPV is sexually transmitted. Subsequent studies revealed a substantial decrease in the prevalence of the four HPV strains targeted by these vaccines, with the rates of infection being cut by at least half. HPV vaccination is recommended for both boys and girls to prevent infection with oncogenic HPV types associated with cervical cancer and other cancers. Nonetheless, the high manufacturing cost of the vaccine has limited access for many people globally.